Literature DB >> 9031090

Nuclear NF-ATp is a hallmark of unstimulated B cells from B-CLL patients.

K Schuh1, A Avots, H P Tony, E Serfling, C Kneitz.   

Abstract

B lymphocytes from the peripheral blood of patients with chronic lymphocytic leukaemia (CLL) were analysed for the nuclear presence and DNA binding of a panel of transcription factors which are involved in the gene control of lymphoid cells. The following transcription factors were studied: the Octamer factors Oct-1 and Oct-2, members of the AP-1 factor family, NF-AT factors, in particular NF-ATp, and members of the Rel/NF-kB family. We show that the constitutive nuclear translocation of NF-ATp, a member of the growing family of NF-AT factors, is a hallmark of nonstimulated B cells from CLL patients that distinguishes B-CLL cells from 'normal' B lymphocytes. Constitutive nuclear appearance was also observed for NF-kB2/p52. Constitutive binding of further factor proteins to DNA, such as JunD, c-Fos and FosB, was detected in several patients whereas the localisation and DNA binding of other factors such as c-Jun, RelA/p65 and c-Rel was unaltered. It is remarkable that in B-CLL cells the nuclear appearance and DNA binding of specific transcription factors is dramatically affected whereas other members of the same factor family remained unaltered in these leukemic cells. It remains to be shown which molecular events lead to the specific 'pre-activation', i.e. constitutive nuclear translocation and DNA binding, of these members of NF-AT, NF-kB and AP-1 factor families.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9031090     DOI: 10.3109/10428199609054868

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  16 in total

Review 1.  Molecular basis of CLL.

Authors:  Yuri Pekarsky; Nicola Zanesi; Carlo M Croce
Journal:  Semin Cancer Biol       Date:  2010-09-21       Impact factor: 15.707

Review 2.  Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.

Authors:  Caspar da Cunha-Bang; Carsten Utoft Niemann
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

3.  13q14 deletions in CLL involve cooperating tumor suppressors.

Authors:  Alexey Palamarchuk; Alexey Efanov; Natalya Nazaryan; Urmila Santanam; Hansjuerg Alder; Laura Rassenti; Thomas Kipps; Carlo M Croce; Yuri Pekarsky
Journal:  Blood       Date:  2010-01-13       Impact factor: 22.113

Review 4.  miR deregulation in CLL.

Authors:  Veronica Balatti; Yuri Pekarky; Lara Rizzotto; Carlo M Croce
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

5.  STAT-3 activates NF-kappaB in chronic lymphocytic leukemia cells.

Authors:  Zhiming Liu; Inbal Hazan-Halevy; David M Harris; Ping Li; Alessandra Ferrajoli; Stefan Faderl; Michael J Keating; Zeev Estrov
Journal:  Mol Cancer Res       Date:  2011-03-01       Impact factor: 5.852

6.  The B lineage transcription factor E2A regulates apoptosis in chronic lymphocytic leukemia (CLL) cells.

Authors:  Lela Kardava; Qi Yang; Anthony St Leger; Kenneth A Foon; Suzanne Lentzsch; Abbe N Vallejo; Christine Milcarek; Lisa Borghesi
Journal:  Int Immunol       Date:  2011-05-06       Impact factor: 4.823

7.  Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-κB signaling.

Authors:  M Hahn; J-P Bürckert; C A Luttenberger; S Klebow; M Hess; M Al-Maarri; M Vogt; S Reißig; M Hallek; A Wienecke-Baldacchino; T Buch; C P Muller; C P Pallasch; F T Wunderlich; A Waisman; N Hövelmeyer
Journal:  Leukemia       Date:  2017-06-01       Impact factor: 11.528

Review 8.  Role of miR-15/16 in CLL.

Authors:  Y Pekarsky; C M Croce
Journal:  Cell Death Differ       Date:  2014-06-27       Impact factor: 15.828

Review 9.  Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.

Authors:  C I Edvard Smith; Jan A Burger
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

10.  Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL.

Authors:  Dimitar G Efremov; Adrian Wiestner; Luca Laurenti
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-10-09       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.